Physician profile
Anna M Decoite
NPI 1154098713
$4,594.10
in general payments reported to CMS, 2019-2025
49 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $401 · 2023: $426 · 2024: $1,847 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175 · Honoraria: $600 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.55 |
| Honoraria | $600.00 |
| Education | $194.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $658.91 | 2024-2025 | Cosela, Monoferric |
| Novartis Pharmaceuticals Corporation | $418.85 | 2022-2025 | |
| Daiichi Sankyo INC. | $288.63 | 2021-2025 | Enhertu, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $280.49 | 2022-2025 | Imfinzi, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $269.23 | 2022 | |
| Incyte Corporation | $238.20 | 2021-2024 | Jakafi |
| Pfizer INC. | $180.61 | 2023-2025 | |
| Janssen Biotech, INC. | $176.53 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Beigene USA, INC. | $160.54 | 2024-2025 | Brukinsa, Tevimbra |
| Merck Sharp & Dohme LLC | $147.89 | 2023-2025 | Keytruda, Reblozyl, Lynparza |
| Abbvie INC. | $130.26 | 2024-2025 | |
| Exelixis INC. | $114.62 | 2024-2025 | Cabometyx |
| Genzyme Corporation | $113.79 | 2024-2025 | |
| G1 Therapeutics, INC. | $84.46 | 2022-2023 | Cosela |
| Adaptive Biotechnologies Corporation | $68.57 | 2024 | Clonoseq |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $68.54 | 2023 | Epkinly, Imbruvica |
| Genentech USA, INC. | $68.19 | 2024 | Itovebi, Tecentriq, Tecentriq Hybreza |
| Regeneron Healthcare Solutions, INC. | $67.14 | 2023-2024 | Libtayo |
| Amgen INC. | $65.32 | 2022-2023 | Kyprolis, Lumakras |
| Genmab U.S., INC. | $62.22 | 2024-2025 | Epkinly |
| Lilly USA, LLC | $62.12 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $51.52 | 2023-2024 | Iclusig, Alunbrig |
| Servier Pharmaceuticals LLC | $51.05 | 2024 | |
| Eisai INC. | $50.11 | 2025 | |
| Coherus Oncology, INC. | $48.41 | 2023-2024 | |
| Array Biopharma INC | $48.14 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| Myriad Genetic Laboratories, INC. | $41.21 | 2023-2024 | Myrisk, Precisetumor |
| Bayer Healthcare Pharmaceuticals INC. | $38.95 | 2025 | |
| Bard Peripheral Vascular, INC. | $38.65 | 2025 | Trek |
| Aveo Pharmaceuticals, INC. | $34.91 | 2024 | |
| Mirati Therapeutics, INC. | $30.89 | 2023 | Krazati |
| Taiho Oncology, INC. | $29.92 | 2024 | |
| Seagen INC. | $29.90 | 2023 | Tivdak |
| Teleflex LLC | $28.07 | 2024 | Arrow |
| Stemline Therapeutics INC. | $28.02 | 2024 | Orserdu |
| Astellas Pharma US INC | $27.95 | 2024-2025 | Vyloy, Xospata |
| Rigel Pharmaceuticals, INC. | $26.70 | 2024 | Rezlidhia, Tavalisse |
| Celgene Corporation | $25.41 | 2024 | Opdualag |
| Blueprint Medicines Corporation | $25.29 | 2024 | Ayvakit |
| Emd Serono, INC. | $24.74 | 2024 | |
| Sobi, INC | $24.39 | 2025 | |
| Tersera Therapeutics LLC | $24.35 | 2024 | Xermelo |
| Glaxosmithkline, LLC. | $23.92 | 2024 | Ojjaara |
| Beone Medicines USA, INC. | $22.80 | 2025 | Brukinsa |
| Geron Corporation | $21.19 | 2025 | Rytelo |
| Puma Biotechnology, INC. | $20.22 | 2024 | |
| Legend Biotech USA INC. | $19.40 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $16.64 | 2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $16.24 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Decoite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.